CHIC Health Achieves World-Leading AI Algorithm Performance for Two Consecutive Years, Paving the Way for Global Digital Therapeutics Leadership

Recently, Qiyi Medical achieved outstanding results in the WMT 2022, a top-tier international machine translation evaluation competition, securing first place in the English-to-Chinese task and second place in the Chinese-to-English task within the biomedical and pharmaceutical domain, outperforming numerous leading AI companies, universities, and research institutions both domestically and internationally.

Prior to this, Qiyi Medical secured second place worldwide in the video track at the MedVidQA 2022 International Medical Video Question Answering Competition held in June. This marks another strong performance by the company following its top ranking overall in the MEDIQA series in 2021.

Achieving outstanding results in top-tier international algorithm competitions reflects Qiyi Medical’s deep accumulation and breakthroughs in the field of AI technology. It comprehensively demonstrates the team’s professional AI R&D capabilities and technical strength, while also establishing a robust technological barrier for the company’s upcoming series of digital therapeutic products.

With the continuous improvement in the quality of machine translation in recent years,WMT2022SeriesThe competition adopts new rules, focusing on improving machine translation inHealthcare, etc.Performance in General Domains. Qiyi Medical’s WMT2022-winning technology from 2022 plays a significant role in the clinical application of its products and in the translation of industry-academia-research collaborations.

“Requirements for AI Models in the Biomedical Translation Tasks We Have Completed”MostHigh.”AlgorithmTeam LeaderIntroduction: The greatest challenge of this task lies in ensuring that the translated sentences are fluent in word order and complete in meaning, while also guaranteeing the accuracy of medical terminology and adherence to the linguistic conventions and practices of the biopharmaceutical field. This rigorously tests the participating teams’ corpus volume and algorithmic capabilities.

"CompanyIn‘English to Chinese’Leading the pack in the task, which means that throughOurAIEnglish literature translated by the translation model can better meet the needs of doctors, helping them quickly understand the content of the literature."Enhance the efficiency of translating clinical research achievements into practical applications."Head of the Medical Department stated。

Ranked First in the WMT2022 Biomedical “English-to-Chinese” Translation Task (Image from the Official WMT Competition)

Ranked 2nd in the WMT 2022 Chinese-to-English Biomedical Translation Task (Image source: WMT Competition Official)

Qiyi Medical 2021YearAnother international competition participated in was the MEDIQA Challenge, a premier event for natural language processing research in the biomedical and pharmaceutical fields.MEDIQA, organized by a team from the National Institutes of Health (NIH), is a leader in natural language processing research within the biomedical field. Qiyi Medical independently designed an attention mechanism based on Markov chain steady states to perform extraction from document-level to sentence-level granularity, thereby facilitating the development of a pre-trained generative summarization model.Victory AchievedFrom numerous leading technology companies and universities both in China and abroadTeam, Achieved the Outstanding Result of Ranking First in the World。

The two competition tasks differ, but both assess teams’ capabilities in medical-domain text understanding and large-scale pre-trained model technologies. “We aim to benchmark our team’s technical capabilities against leading AI teams both in China and abroad, continuously enhancing our algorithmic prowess, with the ultimate goal of applying advanced and mature technologies toActualmedical scenarios.”

The algorithms integrated by Qiyi Medical can be applied to multiple scenarios, including search query translation, medical terminology translation, and literature translation, helping physicians quickly grasp the content of articles. It also excels inFocus on the automated answering of patient inquiries to facilitate higher-quality patient management for digital therapeutics products.The company has built a large-scaleAImodel library, and has been implemented in scenarios such as structured medical records, medical research platforms, and various healthcare quality control applications, receiving consistent positive feedback from customers.

“The company’s advanced algorithmic technologies can better supportWeThroughout the Entire Course of Respiratory DiseasesDigital TherapeuticsDevelopment of Software and Hardware Productsand Applications。”Xu Liwen, Technical Director of Products at Qiyi Medical, stated, currentlyLinked to over 7,000 medical institutions across China, established direct connections with tens of thousands of pulmonologists, accumulated nearly ten million patient data records, and built a database for an innovative management model for respiratory diseases that is leading in scale globally.

Building on this database, the company has collaborated with leading respiratory experts and research institutions in the industry to complete the development of a COPD risk screening model, a COPD acute exacerbation warning model, and a COPD rehabilitation assessment model.Awaiting development, all of which are intellectual property rights of patented technologies independently innovated in China.

“For example,In COPDRiskScreeningDuring the R&D process，Our goal is to enhance the validity and precision of current screening questionnaires. Currently,The accuracy of patient disease risk assessment using the COPD screening questionnaire is approximately 50%.UsageWeofAI"The risk screening model can increase the screening accuracy to over 80%," introduced Xu Liwen.

At this stageThe pipeline of digital therapeutics products under development all benefit from Qiyi Medical's strongAITechnical barriers, andhas gradually expanded from chronic obstructive pulmonary disease (COPD) to asthma, nicotine addiction,Sleep Apnea Syndromeand other respiratorySystemDiseaseDigital Therapeutics Product.

Hong Lei, COO of Qiyi Medical, stated: “We are a technology R&D enterprise with a strong academic background,Attracted participants from Ping An,GEMedical,IQVIAand top-tier talent from medical technology companies and leading domestic tertiary hospitals.Over 60% of its staff are engaged in clinical and technical R&D, and more than half of the team members hold a master’s degree or higher.”Core Team MembersSuccessively Selected“Feifeng Talent Program”and“Taihu Talent Program”，ObtainGovernment and All Sectors of SocietyHighly Recognized。A highly specialized technical team underpins the company’s capability to implement a multi-pipeline business layout.

Furthermore,Continuous investment in scientific research and innovation is the company's technology, productContinuouslySources of Innovation,also marks the approval of its series of digital therapeutics productsNMPACertified Protection。Qiyi Medical, established less than three years ago, inR&DRelatedAspectcumulative investmentOver3000Ten thousandYuan，We will continue to steadily increase our investment in the future.

As of the end of October 2022, Qiyi Medical applied for or obtainedGetNearly 60 software copyrights and patents; more than five multicenter prospective clinical trials on respiratory diseases conducted across China, with nearly 2,500 subjects enrolled in these clinical trials.Estimated2025annual or cumulative20Medical device manufacturing licenses for more than [number] digital therapeutic products,2023AnnualFirst Batch5New Products for Screening, Diagnosis, and Rehabilitation of COPDTheApprovedListing.”

Qiyi Medical, in terms of technical expertise, product pipeline, and commercialization pathwayAllAlready at the forefront of the industry. As an outstanding representative in the field of respiratory care,itsIn the future, it will also shoulder greater industry responsibilities. Beyond focusing on its own product innovation, it will collaborate with industry partners to build an innovative ecosystem for the health industry, creating more possibilities for patients.